About this trial
Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of SARS-CoV-2 infection, the purpose of the study is to investigate whether in patients recovered from COVID-19 disease, SARS-CoV-2 infection has induced: 1) endocrine-metabolic function damage; 2) neuro-psychiatric damage; 3) muscle damage; 4) pulmonary damage; 5) cardiological damage; 6) venous vascular damage; 7) dermatological damage. Patients will be evaluated at baseline (at discharge from infectious and/or pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.
Eligibility criteria
Qualifiers
Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG);
Aged over 18 years of age;
Ability to understand protocol procedures
Disqualifiers
Any psychological/psychiatric/other medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences
uncooperative attitude of the patient
Trial design
Treatments tested in this trial
- Assessments of endocrinological phenotypes of LO-COCO patients
- Assessment of muscular phenotypes of LO-COCO patients
- Assessment of neuropsychiatric phenotypes of LO-COCO patients
- Muscle biopsy
- Assessment of pulmonary phenotypes of LO-COCO patients
- Assessment of cardiological phenotypes of LO-COCO patients
- Assessment of vascular phenotypes of LO-COCO patients
- Assessment of dermatological phenotypes of LO-COCO patients
- Tissue biopsy
Treatment groups
Sponsors and collaborators
Federico II University
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Collaborator